13,14-dihydro-15-keto-tetranor Prostaglandin E2

A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the a-terminus and oxidation of the terminal w-carbon produces the abundant urinary metabolites, including tetranor PGEM.{2127} 13,14-dihydro-15-keto-tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 (Item No. 14650), which is known to have a short plasma half-life.{433,366,581}